Last reviewed · How we verify
NCT03887156: Predictor2
Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft
Phase 2, PHASE3 trial testing Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test in Acute Myeloid Leukemia in Remission in 227 participants. Status unknown.
16 March 2023
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 227 |
| Start date | 16 September 2019 |
| Primary completion | 16 March 2023 |
| Estimated completion | 16 March 2023 |
| Sites | 22 locations across Belgium, France, Germany |
Drugs / interventions tested
- Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Conditions studied
- Acute Myeloid Leukemia in Remission — all drugs for Acute Myeloid Leukemia in Remission →
- Lymphoma in Remission — all drugs for Lymphoma in Remission →
- Non-progressive Myeloproliferative Syndrome — all drugs for Non-progressive Myeloproliferative Syndrome →
- Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts — all drugs for Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
Adults 18 to 65, any sex, with Acute Myeloid Leukemia in Remission or Lymphoma in Remission. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim is to validate an in vitro diagnosis medical device to predict grade II to IV aGVHD after a cell graft
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03887156
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myeloid Leukemia in Remission
Currently open trials in the same condition.
- NCT06440135 — Ziftomenib Maintenance Post Allo-HCT · Phase 1 · recruiting
- NCT06462365 — Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) · Phase 1 · recruiting
- NCT05236764 — Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion · NA · active not recruiting
- NCT05917405 — Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT · Phase 2 · recruiting
- NCT05224661 — Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events · active not recruiting
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03887156 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 28 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03887156.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing